TY - JOUR
T1 - Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system
AU - Stöhr, W.
AU - Langer, T.
AU - Kremers, A.
AU - Bielack, S.
AU - Lamprecht-Dinnesen, A.
AU - Frey, E.
AU - Beck, J. D.
N1 - Funding Information:
This study was supported by ‘‘Deutsche Krebshilfe.’’ Below is a list of participating centers (and the number of study patients). Supporters include both children’s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children’s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children’s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children’s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children’s Hospital, Karlsruhe (1) Prof. Dr. D. Körholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. Jürgens, University Hospital for Children, Münster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, Tübingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. Dölken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1)
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005
Y1 - 2005
N2 - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.
AB - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.
UR - http://www.scopus.com/inward/record.url?scp=18944370353&partnerID=8YFLogxK
U2 - 10.1081/CNV-200055951
DO - 10.1081/CNV-200055951
M3 - Journal articles
C2 - 15945505
AN - SCOPUS:18944370353
SN - 0735-7907
VL - 23
SP - 201
EP - 207
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -
